Can marked hyperglycemia and insulin resistance promote hepatic fat accumulation and mild ALT elevation?

Marked hyperglycemia and insulin resistance commonly coexist in metabolic dysfunction and can contribute to fatty liver biology, but the strength of evidence differs across the proposed sequence.

Clinical and mechanistic evidence

• Insulin resistance has moderate support as a driver of hepatic fat accumulation. Selective hepatic insulin resistance can fail to suppress hepatic glucose production while leaving lipogenesis active; increased adipose lipolysis also raises free-fatty-acid delivery to the liver.
• In human NAFLD metabolic studies, 24-hour elevations in glucose and insulin associated with insulin-resistant metabolism were linked to increased hepatic de novo lipogenesis, mediated by glucose-responsive ChREBP and insulin-responsive SREBP-1c.
• Hyperglycemia is therefore a plausible contributor to steatosis, but its independent contribution cannot be confidently separated from hyperinsulinemia and the broader insulin-resistant state.
• Excess hepatic lipid provides a biologically coherent route to oxidative stress and injury: harmful lipid intermediates, mitochondrial dysfunction, reactive oxygen species, lipid peroxidation, inflammation, and hepatocyte injury. These links are supported chiefly by mechanistic and experimental evidence rather than direct human causal studies relating measured glucose or insulin resistance to oxidative-stress biomarkers or subsequent injury.

ALT and clinical interpretation

• Mild ALT elevation is compatible with hepatocellular injury, but it is nonspecific and does not establish the cause or severity of liver disease. AASLD cites a true-normal ALT range of roughly 29–33 U/L in men.
• Normal ALT is not reassuring enough to exclude clinically important metabolic liver disease: pooled evidence found normal ALT in 25% of NAFLD and 19% of NASH cases.
• At age 77, ALT interpretation is especially limited because ALT tends to decline with age. For diabetes/metabolic-risk settings, fibrosis assessment should extend beyond ALT; for adults over 65, FIB-4 uses a threshold >2.0, followed when indicated by elastography.

Bottom line

• Insulin resistance is supported as a promoter of hepatic fat accumulation; hyperglycemia, oxidative stress, and hepatocellular injury are plausible interconnected consequences, with the latter links predominantly mechanistic. Mild ALT elevation may occur, but neither its presence nor absence reliably defines liver injury or fibrosis.